HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016

HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016
Published Jun 28, 2016
70 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016, provides in depth analysis on HIV-1 Integrase (EC 2.7.7.) targeted pipeline therapeutics.

The report provides comprehensive information on the HIV-1 Integrase (EC 2.7.7.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in HIV-1 Integrase (EC 2.7.7.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for HIV-1 Integrase (EC 2.7.7.)
- The report reviews HIV-1 Integrase (EC 2.7.7.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in HIV-1 Integrase (EC 2.7.7.) targeted therapeutics and enlists all their major and minor projects
- The report assesses HIV-1 Integrase (EC 2.7.7.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to HIV-1 Integrase (EC 2.7.7.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for HIV-1 Integrase (EC 2.7.7.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by

  
Source:
Document ID
GMDHC0170TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
HIV-1 Integrase (EC 2.7.7.) Overview71
Therapeutics Development83
  HIV-1 Integrase (EC 2.7.7.) Products under Development by Stage of Development81
  HIV-1 Integrase (EC 2.7.7.) Products under Development by Therapy Area91
  HIV-1 Integrase (EC 2.7.7.) Products under Development by Indication101
HIV-1 Integrase (EC 2.7.7.) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
HIV-1 Integrase (EC 2.7.7.) Products under Development by Companies132
HIV-1 Integrase (EC 2.7.7.) Products under Development by Universities/Institutes152
HIV-1 Integrase (EC 2.7.7.) Therapeutics Assessment176
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action181
  Assessment by Route of Administration192
  Assessment by Molecule Type212
HIV-1 Integrase (EC 2.7.7.) Companies Involved in Therapeutics Development235
  Critical Outcome Technologies Inc.231
  Gilead Sciences, Inc.241
  Merck &Co., Inc.251
  TGV-Laboratories261
  ViiV Healthcare Limited271
HIV-1 Integrase (EC 2.7.7.) Drug Profiles2821
  (cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate) Drug Profile285
  (dolutegravir sodium + rilpivirine hydrochloride) Drug Profile331
  Antisense RNAi Oligonucleotide to Inhibit HIV-I Integrase for HIV Drug Profile341
  cabotegravir sodium Drug Profile353
  cabotegravir sodium + rilpivirine hydrochloride Drug Profile381
  elvitegravir Drug Profile392
  M-522 Drug Profile411
  M-532 Drug Profile421
  MK-2048 Drug Profile431
  Small Molecule to Inhibit HIV-1 Integrase for HIV infection Drug Profile441
  Small Molecule to Inhibit Integrase for HIV Drug Profile451
  Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection Drug Profile461
  Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection Drug Profile471
  T-169 Drug Profile481
HIV-1 Integrase (EC 2.7.7.) Dormant Projects491
HIV-1 Integrase (EC 2.7.7.) Discontinued Products501
HIV-1 Integrase (EC 2.7.7.) Featured News &Press Releases5118
  Feb 24, 2016: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir511
  Feb 23, 2016: ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment521
  Jan 26, 2016: AHF Files Federal Lawsuit Against Gilead to Invalidate Patents on Key AIDS Drug531
  Dec 07, 2015: Health Canada Issues Notice of Compliance for Gilead's Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection541
  Nov 23, 2015: European Commission Grants Marketing Authorization for Gilead s Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection551
  Nov 05, 2015: U.S. Food and Drug Administration Approves Gilead s Single Tablet Regimen Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection562
  Nov 03, 2015: ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy581
  Oct 22, 2015: Gilead Announces Phase 3 Results for Genvoya (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV582
  Sep 25, 2015: European CHMP Adopts Positive Opinion for Gilead s Single Tablet Regimen Genvoya for the Treatment of HIV601
  Jul 21, 2015: Gilead Announces Phase 3 Results From the First Study to Evaluate Switching From TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)612
  May 06, 2015: ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy631
  Apr 15, 2015: Critical Outcome Technologies Receives First U.S. Patent For Next Generation HIV Treatment641
  Feb 26, 2015: Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide643
  Jan 15, 2015: Long-acting drug effectively prevents HIV-like infection in monkeys671
  Nov 06, 2014: Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV681
Appendix692
  Methodology691
  Coverage691
  Secondary Research691
  Primary Research691
  Expert Panel Validation691
  Contact Us691
  Disclaimer701

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/HIV-1-Integrase-EC-2-7-7-Pipeline-Review-H1-2016-2088-16058>
  
APA:
Global Markets Direct - Market Research. (2016). HIV-1 Integrase (EC 2.7.7.) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/HIV-1-Integrase-EC-2-7-7-Pipeline-Review-H1-2016-2088-16058>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.